Summary
Polyoxometalates could be viewed as the molecular counterpart of the metal oxides, which are essential ingredients for various energy conversion and storage applications. In this manuscript, we review the progress of engineering functional polyoxometalates toward energy applications, focusing on, but not limited to, polyoxotitanate, polyoxotungstate, and polyoxomolybdate. These polyoxometalates are considered to be promising candidates for dye‐sensitized solar cell, perovskite solar cell, lithium‐ion battery, lithium‐sulfur battery, supercapacitor, and water‐splitting system. We believe advanced energy devices with better performance could be derived from further engineering the polyoxometalates owing to their molecular design flexibility.
In the present study, we investigated the effect of lipoxin A4 on myocardial ischemia-reperfusion injury (IRI) following cardiac arrest (CA) in a rabbit model. Lipoxin A4 is a metabolite of arachidonic acid in the eicosanoid, it is called "brake signal" for its anti-inflammatory activity. Some inflammatory factors (IL-1β, IL-6, TNF-α, and IL-10), NF-κB p65, infarct ratios, apoptotic index, cardiac troponin I (cTnI), hemodynamic and myocardial structures were measured or observed in different groups. Lipoxin A4 inhibits the expression of IL-1β, IL-6, and TNF-α, the values of the infarct ratios, apoptotic index, the level of serum cTnI and NF-κB p65. Meanwhile, it improves the expression of IL-10, hemodynamic, myocardial structure, and function. These indicate that lipoxin A4 mitigates postresuscitation myocardial IRI in which anti-inflammation and suppression of NF-κB activation may play an important role.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.